Key Points
- CEO insider sale: Replimune CEO Sushil Patel sold 10,000 shares on Dec. 2 at an average of $11.13 for $111,300, trimming his direct stake to 333,576 shares (a 2.91% decrease).
- Stock and financials: REPL traded near $10.45 (12‑month range $2.68–$14.80) with a market cap around $819.7M, and the company reported a quarterly loss of $0.90 per share with analysts projecting a negative EPS for the year.
- Institutional and analyst backdrop: Institutional investors own about 92.5% of the stock, several brokerages have recently upgraded REPL, and the consensus rating is a "Moderate Buy" with a $9.75 target.
Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) CEO Sushil Patel sold 10,000 shares of the business's stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $11.13, for a total transaction of $111,300.00. Following the completion of the sale, the chief executive officer directly owned 333,576 shares in the company, valued at $3,712,700.88. This represents a 2.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Replimune Group Stock Down 0.8%
REPL stock traded down $0.08 during trading hours on Friday, reaching $10.45. 67,479 shares of the stock were exchanged, compared to its average volume of 4,261,384. The firm's 50-day moving average is $7.75 and its 200-day moving average is $7.56. Replimune Group, Inc. has a 12 month low of $2.68 and a 12 month high of $14.80. The company has a market cap of $819.70 million, a price-to-earnings ratio of -3.04 and a beta of 0.66. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.31 and a quick ratio of 6.31.
Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.03). On average, equities research analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current year.
Institutional Trading of Replimune Group
A number of large investors have recently added to or reduced their stakes in REPL. Goldman Sachs Group Inc. grew its holdings in Replimune Group by 20.9% during the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company's stock worth $6,729,000 after purchasing an additional 119,145 shares during the period. Exome Asset Management LLC raised its stake in Replimune Group by 438.6% in the first quarter. Exome Asset Management LLC now owns 294,846 shares of the company's stock valued at $2,875,000 after buying an additional 240,108 shares during the period. Nuveen LLC acquired a new stake in shares of Replimune Group in the first quarter valued at approximately $6,546,000. Deutsche Bank AG boosted its stake in shares of Replimune Group by 0.4% during the 1st quarter. Deutsche Bank AG now owns 563,701 shares of the company's stock worth $5,496,000 after acquiring an additional 2,140 shares during the period. Finally, Nan Fung Trinity HK Ltd. acquired a new position in shares of Replimune Group during the 2nd quarter worth approximately $4,325,000. Institutional investors and hedge funds own 92.53% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on REPL. HC Wainwright raised shares of Replimune Group from a "neutral" rating to a "buy" rating and set a $12.00 price target for the company in a research note on Monday, October 27th. Piper Sandler raised shares of Replimune Group from a "neutral" rating to an "overweight" rating and set a $13.00 target price for the company in a research report on Monday, October 20th. Wedbush upgraded shares of Replimune Group from a "neutral" rating to an "outperform" rating and lifted their price target for the company from $4.00 to $18.00 in a research note on Monday, October 20th. Leerink Partners upgraded shares of Replimune Group from a "market perform" rating to an "outperform" rating and increased their price objective for the stock from $3.00 to $13.00 in a research note on Monday, October 20th. Finally, JPMorgan Chase & Co. raised Replimune Group from an "underweight" rating to a "neutral" rating and set a $11.00 target price on the stock in a research report on Monday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $9.75.
Read Our Latest Analysis on Replimune Group
Replimune Group Company Profile
(
Get Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
